News & Media

Recent updates from Arcutis.

July 5, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2022

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

June 3, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 25, 2022

Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

May 5, 2022

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

May 5, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 6, 2022

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

March 28, 2022

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

March 25, 2022

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

March 25, 2022

Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study

March 22, 2022

National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments

March 21, 2022

Arcutis to Host Investor Day on March 28

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download